Contact

All Stories

  1. Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

    Article • Blood, December 2025, American Society of Hematology

    Prof. Emanuele Zucca

  2. Dual targeting of BTK and BCL2 enhances apoptosis in marginal zone lymphoma models: preclinical activity of BGB-16673 and sonrotoclax

    Article • November 2025, Cold Spring Harbor Laboratory Press

    Prof. Emanuele Zucca

  3. SOHO State of the Art Updates and Next Questions: Treatment Options for Marginal Zone Lymphoma

    Article • Clinical Lymphoma Myeloma & Leukemia, July 2025, Elsevier

    Prof. Emanuele Zucca

  4. Early Complete Response as Validated Surrogate Marker in Extranodal Marginal Zone Lymphoma Systemic Therapy

    Article • Blood, October 2023, American Society of Hematology

    Prof. Emanuele Zucca

  5. 17th International Conference on Malignant Lymphoma: Key Takeaways

    Article • Blood Cancer Discovery, August 2023, American Association for Cancer Research (AACR)

    Prof. Emanuele Zucca

  6. Targeting CD25-positive lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as single agent or in combination with targeted agents

    Article • July 2023, Cold Spring Harbor Laboratory Press

    Prof. Emanuele Zucca

  7. Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors

    Article • Journal of Clinical Medicine, January 2023, MDPI AG

    Prof. Emanuele Zucca

  8. Extranodales Marginalzonenlymphom des mukosaassoziierten lymphatischen Gewebes (MALT-Lymphom)

    Article • January 2023, Springer Science + Business Media

    Prof. Emanuele Zucca

  9. D max : A simple and reliable PET/CT‐derived new biomarker of lymphoma outcome?

    Article • Hematological Oncology, July 2022, Wiley

    Prof. Emanuele Zucca

  10. Finding a consensus on time‐to‐event endpoints definitions in marginal zone lymphoma: A Delphi method

    Article • Hematological Oncology, April 2022, Wiley

    Prof. Emanuele Zucca

  11. Integration of Baseline Metabolic Parameters and Mutational Profiles Predicts Long-Term Response to First-Line Therapy in DLBCL Patients: A Post Hoc Analysis of the SAKK38/07 Study

    Article • Cancers, February 2022, MDPI AG

    Prof. Emanuele Zucca

  12. Marginal-Zone Lymphomas

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2022, New England Journal of Medicine (NEJM/MMS)

    Prof. Emanuele Zucca

  13. PET imaging of lymphomas

    Article • January 2022, Elsevier

    Prof. Emanuele Zucca

  14. Radiomics in Malignant Lymphomas

    Article • December 2021, Biogenic Press

    Prof. Emanuele Zucca

  15. A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas

    Article • Hematological Oncology, November 2020, Wiley

    Prof. Emanuele Zucca

  16. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B‐cell lymphoma: post‐hoc analysis from the SAKK38/07 clinical trial

    Article • Hematological Oncology, October 2020, Wiley

    Prof. Emanuele Zucca

  17. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

    Article • Blood, July 2019, American Society of Hematology

    Prof. Emanuele Zucca

  18. Foreword

    Article • European Journal of Internal Medicine, December 2018, Elsevier

    Prof. Emanuele Zucca

  19. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals

    Article • Hematological Oncology, August 2018, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  20. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma

    Article • Blood, July 2018, American Society of Hematology

    Prof. Emanuele Zucca

  21. Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas

    Article • Clinical Cancer Research, July 2018, American Association for Cancer Research (AACR)

    Prof. Emanuele Zucca

  22. Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma

    Article • Blood, May 2018, American Society of Hematology

    Prof. Emanuele Zucca

  23. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review

    Article • Annals of Oncology, May 2018, Elsevier

    Prof. Emanuele Zucca

  24. Novel acquisitions on biology and management of transformed follicular lymphoma

    Article • Hematological Oncology, March 2018, Wiley

    Prof. Emanuele Zucca

  25. Recent advances in understanding the biology of marginal zone lymphoma

    Article • F1000Research, March 2018, Faculty of 1000, Ltd.

    Emanuele Zucca, Dr Francesco Bertoni, Prof. Emanuele Zucca

  26. ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma

    Article • Annals of Oncology, March 2018, Elsevier

    Prof. Emanuele Zucca

  27. Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias

    Article • Haematologica, February 2018, Ferrata Storti Foundation (Haematologica)

    Prof. Emanuele Zucca

  28. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study

    Article • Investigational New Drugs, February 2018, Springer Science + Business Media

    Prof. Emanuele Zucca

  29. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia

    Article • Annals of Oncology, February 2018, Elsevier

    Prof. Emanuele Zucca

  30. Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas

    Article • Annals of Oncology, February 2018, Elsevier

    Prof. Emanuele Zucca

  31. PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy

    Article • Clinical Cancer Research, January 2018, American Association for Cancer Research (AACR)

    Prof. Emanuele Zucca

  32. Tailoring treatment for MALT lymphoma patients: where do we stand now?

    Article • Oncotarget, December 2017, Impact Journals, LLC

    Prof. Emanuele Zucca

  33. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranoda...

    Article • The Lancet Haematology, November 2017, Elsevier

    Prof. Emanuele Zucca

  34. A MALT lymphoma prognostic index

    Article • Blood, September 2017, American Society of Hematology

    Prof. Emanuele Zucca

  35. Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma

    Article • British Journal of Haematology, June 2017, Wiley

    Dr Francesco Bertoni, Luciano Cascione, Prof. Emanuele Zucca

  36. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions

    Article • Hematological Oncology, June 2017, Wiley

    Luciano Cascione, Prof. Emanuele Zucca

  37. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy

    Article • Journal of Clinical Oncology, June 2017, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  38. Unmet needs in the scientific approach to older patients with lymphoma

    Article • Haematologica, May 2017, Ferrata Storti Foundation (Haematologica)

    Prof. Emanuele Zucca

  39. Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study

    Article • British Journal of Haematology, May 2017, Wiley

    MD Ph.D. Luca LG Giovanella, Prof. Emanuele Zucca

  40. Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015

    Article • Hematological Oncology, April 2017, Wiley

    Prof. Emanuele Zucca

  41. Report of the 6th International Workshop on PET in lymphoma

    Article • Leukemia & Lymphoma, March 2017, Taylor & Francis

    prof Won Seog Kim, Egesta Lopci, Prof. Emanuele Zucca

  42. In Reply to Adams and Kwee

    Article • International Journal of Radiation Oncology*Biology*Physics, March 2017, Elsevier

    Prof. Emanuele Zucca

  43. Clinical aspects and therapy of gastrointestinal MALT lymphoma

    Article • Best Practice & Research Clinical Haematology, March 2017, Elsevier

    Prof. Emanuele Zucca

  44. Marginal zone lymphomas: Reconsidering similarities and differences while moving towards personalized treatment

    Article • Best Practice & Research Clinical Haematology, March 2017, Elsevier

    Prof. Emanuele Zucca

  45. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials

    Article • Journal of Clinical Oncology, February 2017, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  46. Rituximab: 13 open questions after 20years of clinical use

    Article • Cancer Treatment Reviews, February 2017, Elsevier

    Prof. Emanuele Zucca

  47. Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma

    Article • International Journal of Radiation Oncology*Biology*Physics, January 2017, Elsevier

    Prof. Emanuele Zucca

  48. The landscape of new drugs in lymphoma

    Article • Nature Reviews Clinical Oncology, December 2016, Springer Science + Business Media

    Prof. Emanuele Zucca

  49. ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia

    Article • Annals of Oncology, December 2016, Elsevier

    Prof. Emanuele Zucca

  50. SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

    Article • Mediterranean Journal of Hematology and Infectious Diseases, November 2016, Institute of Hematology, Catholic University

    Prof. Emanuele Zucca

  51. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?

    Article • Leukemia & Lymphoma, November 2016, Taylor & Francis

    Prof. Emanuele Zucca

  52. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Article • Annals of Oncology, September 2016, Elsevier

    Prof. Emanuele Zucca

  53. Training improves the interobserver agreement of the expert positron emission tomography review panel in primary mediastinal B-cell lymphoma: interim analysis in the ongoing International Extranodal Lymphoma Study Group-37 study

    Article • Hematological Oncology, August 2016, Wiley

    Prof. Emanuele Zucca

  54. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strongin vivoantitumor activity in lymphoma

    Article • Oncotarget, August 2016, Impact Journals, LLC

    Prof. Emanuele Zucca

  55. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas

    Article • Annals of Oncology, June 2016, Elsevier

    Prof. Emanuele Zucca

  56. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

    Article • The Lancet Haematology, May 2016, Elsevier

    Prof Letterio S Politi, Prof. Emanuele Zucca

  57. Clinical Response of Carcinomas Harboring the BRD4–NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628

    Article • Cancer Discovery, May 2016, American Association for Cancer Research (AACR)

    Prof. Emanuele Zucca

  58. The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance

    Article • Blood, April 2016, American Society of Hematology

    Prof. Emanuele Zucca

  59. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

    Article • The Lancet Haematology, April 2016, Elsevier

    Prof. Emanuele Zucca

  60. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08

    Article • British Journal of Haematology, March 2016, Wiley

    Prof. Emanuele Zucca

  61. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis

    Article • Annals of Oncology, March 2016, Elsevier

    Prof. Emanuele Zucca

  62. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

    Article • Journal of Clinical Oncology, February 2016, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  63. Functional Imaging Using 18-Fluorodeoxyglucose PET in the Management of Primary Mediastinal Large B-Cell Lymphoma: The Contributions of the International Extranodal Lymphoma Study Group

    Article • American Society of Clinical Oncology Educational Book, January 2016, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  64. Hepatitis C virus-associated B-cell non-Hodgkin’s lymphomas: what do we know?

    Article • Therapeutic Advances in Hematology, December 2015, SAGE Publications

    Prof. Emanuele Zucca

  65. Reply to G. Keramida et al

    Article • Journal of Clinical Oncology, December 2015, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  66. Histologic transformation in marginal zone lymphomas

    Article • Annals of Oncology, November 2015, Elsevier

    Prof. Emanuele Zucca

  67. Life expectancy of young adults with follicular lymphoma

    Article • Annals of Oncology, November 2015, Elsevier

    Prof. Emanuele Zucca

  68. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma

    Article • Blood, August 2015, American Society of Hematology

    Prof. Emanuele Zucca

  69. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41)

    Article • The Oncologist, August 2015, Oxford University Press (OUP)

    Prof. Emanuele Zucca

  70. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07)

    Article • Journal of Clinical Oncology, August 2015, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  71. The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models

    Article • British Journal of Haematology, August 2015, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  72. A retrospective international study on primary extranodal marginal zone lymphoma of the lung (BALT lymphoma) on behalf of International Extranodal Lymphoma Study Group (IELSG)

    Article • Hematological Oncology, July 2015, Wiley

    Prof. Emanuele Zucca

  73. A Case of Hodgkin Lymphoma in a Patient with a History of Bone Pain and an Initial Diagnosis of Chronic Osteomyelitis

    Article • Tumori Journal, May 2015, SAGE Publications

    Prof. Emanuele Zucca

  74. Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al

    Article • Journal of Clinical Oncology, April 2015, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  75. Primary and secondary bone lymphomas

    Article • Cancer Treatment Reviews, March 2015, Elsevier

    Prof. Emanuele Zucca

  76. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

    Article • Clinical Cancer Research, January 2015, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Luciano Cascione, Prof. Emanuele Zucca

  77. DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features

    Article • Blood, January 2015, American Society of Hematology

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  78. Genetic lesions in diffuse large B-cell lymphomas

    Article • Annals of Oncology, January 2015, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  79. Management of the Marginal Zone Lymphomas

    Article • January 2015, Springer Science + Business Media

    Prof. Emanuele Zucca

  80. Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response

    Article • Oncotarget, December 2014, Impact Journals, LLC

    Prof. Emanuele Zucca

  81. Hepatitis C virus-associated B-cell non-Hodgkin lymphomas

    Article • Hematology, December 2014, American Society of Hematology

    Prof. Emanuele Zucca

  82. In Reply

    Article • The Oncologist, October 2014, Oxford University Press (OUP)

    Prof. Emanuele Zucca

  83. Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas

    Article • Clinical Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  84. PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas

    Article • Leukemia & Lymphoma, October 2014, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  85. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma

    Article • Cancer Treatment Reviews, October 2014, Elsevier

    Prof. Emanuele Zucca

  86. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

    Article • Journal of Clinical Oncology, September 2014, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  87. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

    Article • Journal of Clinical Oncology, September 2014, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  88. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis

    Article • Hematological Oncology, July 2014, Wiley

    Ramin Sadeghi, Prof. Emanuele Zucca

  89. [18F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study

    Article • Journal of Clinical Oncology, June 2014, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  90. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

    Article • Annals of Oncology, April 2014, Oxford University Press (OUP)

    Giovanni Lo Re, Prof. Emanuele Zucca

  91. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group

    Article • British Journal of Haematology, March 2014, Wiley

    Prof. Emanuele Zucca

  92. Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)

    Article • The Oncologist, February 2014, Oxford University Press (OUP)

    Prof. Emanuele Zucca

  93. The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)

    Article • Leukemia & Lymphoma, February 2014, Taylor & Francis

    Prof. Emanuele Zucca

  94. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)

    Article • British Journal of Haematology, January 2014, Wiley

    Prof. Emanuele Zucca

  95. The clinical features, management and prognostic effects of pathological fractures in a multicenter series of 373 patients with diffuse large B-cell lymphoma of the bone

    Article • Annals of Oncology, January 2014, Elsevier

    Prof. Emanuele Zucca

  96. Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas

    Article • British Journal of Haematology, December 2013, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  97. Prognostic impact of monocyte count at presentation in mantle cell lymphoma - response to Georgeet al

    Article • British Journal of Haematology, November 2013, Wiley

    Prof. Emanuele Zucca

  98. Discovering Subgroups of Patients from DNA Copy Number Data Using NMF on Compacted Matrices

    Article • PLOS One, November 2013, PLOS

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  99. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Article • Annals of Oncology, October 2013, Elsevier

    Prof. Emanuele Zucca

  100. Open questions in the management of mantle cell lymphoma

    Article • Cancer Treatment Reviews, October 2013, Elsevier

    Prof. Emanuele Zucca

  101. Ten Years of International Primary CNS Lymphoma Collaborative Group Studies

    Article • Journal of Clinical Oncology, September 2013, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  102. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma

    Article • Blood, September 2013, American Society of Hematology

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  103. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome

    Article • Blood, September 2013, American Society of Hematology

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  104. Treatment for patients with indolent and mantle cell lymphoma

    Article • The Lancet, September 2013, Elsevier

    Prof. Emanuele Zucca

  105. Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)

    Article • Annals of Hematology, August 2013, Springer Science + Business Media

    Prof. Emanuele Zucca

  106. Toward New Treatments for Mantle-Cell Lymphoma?

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2013, New England Journal of Medicine (NEJM/MMS)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  107. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma

    Article • Blood, August 2013, American Society of Hematology

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  108. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ fromde novodiffuse large B-cell lymphoma

    Article • British Journal of Haematology, August 2013, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  109. The changing paradigm of chronic lymphocytic leukemia management

    Article • European Journal of Internal Medicine, July 2013, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  110. Prognostic impact of monocyte count at presentation in mantle cell lymphoma

    Article • British Journal of Haematology, June 2013, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  111. Genome-wide high resolution DNA profiling of hairy cell leukaemia

    Article • British Journal of Haematology, May 2013, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  112. Extranodal NK/T-cell lymphoma with leukaemic presentation

    Article • British Journal of Haematology, May 2013, Wiley

    Prof. Emanuele Zucca

  113. Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study

    Article • Annals of Oncology, May 2013, Elsevier

    Prof. Emanuele Zucca, Professor Lena Specht

  114. Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial

    Article • Annals of Hematology, April 2013, Springer Science + Business Media

    Prof. Emanuele Zucca

  115. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma

    Article • Annals of Oncology, April 2013, Elsevier

    Prof. Emanuele Zucca

  116. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

    Article • Annals of Oncology, March 2013, Elsevier

    Prof. Emanuele Zucca

  117. Risk factors of central nervous system relapse in mantle cell lymphoma

    Article • Leukemia & Lymphoma, February 2013, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  118. Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study

    Article • Journal of Clinical Oncology, February 2013, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  119. Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH

    Article • Annals of Oncology, January 2013, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  120. Genome-Wide DNA Profiling of HIV-Related B-Cell Lymphomas

    Article • January 2013, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  121. Gains ofCCND3gene in ocular adnexal MALT lymphomas: an integrated analysis

    Article • British Journal of Haematology, December 2012, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  122. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma

    Article • Haematologica, October 2012, Ferrata Storti Foundation (Haematologica)

    Prof. Emanuele Zucca

  123. Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice

    Article • British Journal of Haematology, October 2012, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  124. 18F-FDG Uptake Changes in Liver and Mediastinum During Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

    Article • Clinical Nuclear Medicine, October 2012, Wolters Kluwer Health

    Prof. Emanuele Zucca

  125. Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy

    Article • Leukemia & Lymphoma, September 2012, Taylor & Francis

    Prof. Emanuele Zucca

  126. Chlamydophila Psittaci Eradication With Doxycycline As First-Line Targeted Therapy for Ocular Adnexae Lymphoma: Final Results of an International Phase II Trial

    Article • Journal of Clinical Oncology, July 2012, American Society of Clinical Oncology (ASCO)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  127. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone)

    Article • Leukemia & Lymphoma, July 2012, Taylor & Francis

    Prof. Emanuele Zucca

  128. Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells

    Article • Cancer Science, June 2012, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  129. MYD88 somatic mutations in MALT lymphomas

    Article • British Journal of Haematology, May 2012, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  130. Weekly and 3-weekly cisplatin concurrent with intensity-modulated radiotherapy in locally advanced head and neck squamous cell cancer

    Article • Oral Oncology, March 2012, Elsevier

    Prof. Emanuele Zucca

  131. Incidence, risk factors and outcome of histological transformation in follicular lymphoma

    Article • British Journal of Haematology, February 2012, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  132. Primary Bone Marrow Lymphoma

    Article • The American Journal of Surgical Pathology, February 2012, Wolters Kluwer Health

    Prof. Emanuele Zucca

  133. IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia

    Article • Journal of Translational Medicine, January 2012, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  134. Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate

    Article • British Journal of Clinical Pharmacology, January 2012, Wiley

    Prof. Emanuele Zucca

  135. Absence of NOTCH1 gene mutations in MALT lymphomas

    Article • British Journal of Haematology, December 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  136. Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array

    Article • British Journal of Haematology, November 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  137. Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group

    Article • Hematological Oncology, November 2011, Wiley

    Prof. Emanuele Zucca

  138. Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma

    Article • Leukemia & Lymphoma, August 2011, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  139. Diagnosis and treatment of follicular lymphoma

    Article • Swiss Medical Weekly, August 2011, SMW Supporting Association

    Prof. Emanuele Zucca

  140. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia

    Article • British Journal of Haematology, July 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  141. First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial

    Article • Journal of Clinical Oncology, July 2011, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  142. Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion

    Article • Annals of Oncology, June 2011, Oxford University Press (OUP)

    Dr Francesco Bertoni, Josep Nomdedeu, Prof. Emanuele Zucca

  143. Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype

    Article • Hematological Oncology, June 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  144. Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines

    Article • Leukemia Research, June 2011, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  145. Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP

    Article • British Journal of Haematology, April 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  146. Genomic profiles of MALT lymphomas: variability across anatomical sites

    Article • Haematologica, April 2011, Ferrata Storti Foundation (Haematologica)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  147. Integrated profiling of diffuse large B‐cell lymphoma with 7q gain

    Article • British Journal of Haematology, March 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  148. In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas

    Article • Hematological Oncology, March 2011, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  149. Epidemiology and management of lymphoma in low‐income countries

    Article • Hematological Oncology, March 2011, Wiley

    Professor Ian T Magrath, Prof. Emanuele Zucca

  150. Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome

    Article • Hematological Oncology, March 2011, Wiley

    Dr Francesco Bertoni, Josep Nomdedeu, Prof. Emanuele Zucca

  151. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)

    Article • Annals of Oncology, March 2011, Elsevier

    Prof. Emanuele Zucca

  152. Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination

    Article • The Oncologist, February 2011, Oxford University Press (OUP)

    Prof. Emanuele Zucca

  153. High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study

    Article • Leukemia & Lymphoma, February 2011, Taylor & Francis

    Prof. Emanuele Zucca

  154. Pegfilgrastim to accelerate neutrophil engraftment following peripheral blood stem cell transplant and reduce the duration of neutropenia, hospitalization, and use of intravenous antibiotics: a phase II study in multiple myeloma and lymphoma and compar...

    Article • Leukemia & Lymphoma, February 2011, Taylor & Francis

    Prof. Emanuele Zucca

  155. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome

    Article • Blood, November 2010, American Society of Hematology

    Dr Francesco Bertoni, Claudio Tripodo, Prof. Emanuele Zucca

  156. Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98

    Article • Journal of Clinical Oncology, October 2010, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  157. Immunogenetics features and genomic lesions in splenic marginal zone lymphoma

    Article • British Journal of Haematology, September 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  158. Syk expression patterns differ among B-cell lymphomas

    Article • Leukemia Research, September 2010, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  159. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21

    Article • British Journal of Haematology, August 2010, Wiley

    Dr Francesco Bertoni, Josep Nomdedeu, Prof. Emanuele Zucca

  160. Flows and flaws in primary central nervous system lymphoma

    Article • Nature Reviews Clinical Oncology, August 2010, Springer Science + Business Media

    Prof. Emanuele Zucca

  161. Marginal zone lymphomas

    Article • July 2010, Taylor & Francis

    Prof. Emanuele Zucca

  162. Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia

    Article • Hematological Oncology, July 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  163. Treatment of gastric marginal zone lymphoma of MALT type

    Article • Expert Opinion on Pharmacotherapy, June 2010, Informa Healthcare

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  164. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Article • Annals of Oncology, May 2010, Elsevier

    Prof. Emanuele Zucca

  165. Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms

    Article • British Journal of Haematology, April 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  166. IGHD3-3fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia

    Article • British Journal of Haematology, April 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  167. Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma

    Article • British Journal of Haematology, March 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  168. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial

    Article • British Journal of Cancer, February 2010, Springer Science + Business Media

    Prof. Emanuele Zucca

  169. Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features

    Article • Clinical Cancer Research, January 2010, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  170. Serotonin Receptor 3A Expression in Normal and Neoplastic B Cells

    Article • Pathobiology, January 2010, Karger Publishers

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  171. Genome wide DNA-profiling of HIV-related B-cell lymphomas

    Article • British Journal of Haematology, January 2010, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  172. Response: CNS prophylaxis in MCL

    Article • Blood, December 2009, American Society of Hematology

    Prof. Emanuele Zucca

  173. Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas

    Article • Hematological Oncology, December 2009, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  174. Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group

    Article • Annals of Oncology, December 2009, Elsevier

    Prof. Emanuele Zucca

  175. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

    Article • The Lancet, October 2009, Elsevier

    Prof. Emanuele Zucca

  176. A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03

    Article • Hematological Oncology, September 2009, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  177. How I treat mantle cell lymphoma

    Article • Blood, August 2009, American Society of Hematology

    Prof. Emanuele Zucca

  178. Stereotyped B-Cell Receptor Is an Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome

    Article • Clinical Cancer Research, June 2009, American Association for Cancer Research (AACR)

    Dr Francesco Bertoni, Josep Nomdedeu, Prof. Emanuele Zucca

  179. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome

    Article • Human Pathology, May 2009, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  180. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

    Article • Annals of Oncology, May 2009, Elsevier

    Prof. Emanuele Zucca

  181. Prognosis of Acute Myeloid Leukemia in the General Population: Data from Southern Switzerland

    Article • Tumori Journal, May 2009, SAGE Publications

    Prof. Emanuele Zucca

  182. The NF- B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas

    Article • Blood, March 2009, American Society of Hematology

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  183. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type

    Article • Annals of Oncology, February 2009, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  184. Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study

    Article • British Journal of Haematology, February 2009, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  185. Chlorambucilversusobservation after anti-Helicobactertherapy in gastric MALT lymphomas: results of the international randomised LY03 trial

    Article • British Journal of Haematology, February 2009, Wiley

    Prof. Emanuele Zucca

  186. Extrinsic compression of the pulmonary artery by primary mediastinal large B-cell lymphoma

    Article • British Journal of Haematology, February 2009, Wiley

    Prof. Emanuele Zucca

  187. Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy aloneversuschemotherapy + involved field radiotherapy

    Article • Leukemia & Lymphoma, January 2009, Taylor & Francis

    Prof. Emanuele Zucca

  188. First-line treatment of follicular lymphoma–a patient-oriented algorithm

    Article • Leukemia & Lymphoma, January 2009, Taylor & Francis

    Prof. Emanuele Zucca

  189. Can Rituximab Change the Usually Dismal Prognosis of Patients With Intravascular Large B-Cell Lymphoma?

    Article • Journal of Clinical Oncology, November 2008, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  190. Marginal Zone Lymphomas

    Article • Hematology/Oncology Clinics of North America, October 2008, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  191. The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B-cell lymphoma

    Article • British Journal of Haematology, October 2008, Wiley

    Prof. Emanuele Zucca

  192. The impact of histopathologic diagnosis on the proper management of testis neoplasms

    Article • Nature Clinical Practice Urology, August 2008, Springer Science + Business Media

    Prof. Emanuele Zucca

  193. Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion

    Article • British Journal of Haematology, August 2008, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  194. Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma

    Article • British Journal of Haematology, August 2008, Wiley

    Prof. Emanuele Zucca

  195. Primary testicular lymphoma

    Article • July 2008, Taylor & Francis

    Prof. Emanuele Zucca

  196. Challenging issues in the management of extranodal lymphomas

    Article • July 2008, Taylor & Francis

    Prof. Emanuele Zucca

  197. Extranodal Lymphomas

    Article • July 2008, Taylor & Francis

    Prof. Emanuele Zucca

  198. Gastrointestinal tract lymphomas

    Article • July 2008, Taylor & Francis

    Prof. Emanuele Zucca

  199. Who should receive myeloablative therapy for diffuse large B-cell lymphoma?

    Article • Nature Clinical Practice Urology, July 2008, Springer Science + Business Media

    Prof. Emanuele Zucca

  200. 99mTc-sestamibi imaging and bone marrow karyotyping in the assessment of multiple myeloma and MGUS

    Article • Nuclear Medicine Communications, June 2008, Wolters Kluwer Health

    Prof. Emanuele Zucca

  201. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

    Article • Annals of Oncology, May 2008, Elsevier

    Prof. Emanuele Zucca

  202. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report

    Article • Blood, February 2008, American Society of Hematology

    Prof. Emanuele Zucca

  203. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group

    Article • Annals of Oncology, February 2008, Elsevier

    Prof. Emanuele Zucca

  204. Primary testicular lymphoma

    Article • Critical Reviews in Oncology/Hematology, February 2008, Elsevier

    Prof. Emanuele Zucca

  205. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy

    Article • Annals of Oncology, January 2008, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  206. Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review

    Article • Hematological Oncology, January 2008, Wiley

    Prof. Emanuele Zucca

  207. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment

    Article • Leukemia & Lymphoma, January 2008, Taylor & Francis

    Prof. Emanuele Zucca

  208. Primary CNS Lymphomas Prognosis

    Article • Journal of Clinical Oncology, September 2007, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  209. Marginal-zone lymphoma

    Article • Critical Reviews in Oncology/Hematology, September 2007, Elsevier

    Prof. Emanuele Zucca

  210. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas

    Article • British Journal of Haematology, August 2007, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  211. Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting

    Article • Journal of Clinical Oncology, July 2007, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  212. Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases

    Article • Human Pathology, May 2007, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  213. Gastric marginal zone lymphoma of mucosa-associated lymphoid tissue type: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

    Article • Annals of Oncology, May 2007, Elsevier

    Prof. Emanuele Zucca

  214. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions

    Article • Haematologica, April 2007, Ferrata Storti Foundation (Haematologica)

    Prof. Emanuele Zucca

  215. Revised Response Criteria for Malignant Lymphoma

    Article • Journal of Clinical Oncology, February 2007, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca, Professor Lena Specht

  216. Epidemiology of hematological malignancies

    Article • Annals of Oncology, February 2007, Elsevier

    Prof. Emanuele Zucca

  217. Management of elderly patients with hematological neoplasms

    Article • Annals of Oncology, February 2007, Elsevier

    Prof. Emanuele Zucca

  218. Bendamustine in lymphomas: More to combine?

    Article • Leukemia & Lymphoma, January 2007, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  219. ConcomitantMYCand microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma

    Article • Leukemia & Lymphoma, January 2007, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  220. Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type

    Article • Hematological Oncology, January 2007, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  221. Low prevalence ofChlamydia psittaciin ocular adnexal lymphomas from Cuban patients

    Article • Leukemia & Lymphoma, January 2007, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  222. A Virtual Tissue Bank for Primary Central Nervous System Lymphomas in Immunocompetent Individuals

    Article • Pathobiology, January 2007, Karger Publishers

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  223. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years?

    Article • British Journal of Haematology, December 2006, Wiley

    Prof. Emanuele Zucca

  224. Chlamydia or Not Chlamydia, That Is the Question: Which Is the Microorganism Associated With MALT Lymphomas of the Ocular Adnexa?

    Article • JNCI Journal of the National Cancer Institute, October 2006, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  225. Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas

    Article • British Journal of Haematology, July 2006, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  226. Marginal Zone B-Cell Lymphomas

    Article • January 2006, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  227. Delving deeper into MALT lymphoma biology

    Article • Journal of Clinical Investigation, December 2005, American Society for Clinical Investigation

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  228. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

    Article • British Journal of Haematology, December 2005, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  229. Primary Pulmonary Lymphoma: Current Status

    Article • Clinical Lymphoma & Myeloma, November 2005, Elsevier

    Prof. Emanuele Zucca

  230. State-of-the-Art Therapeutics: Marginal-Zone Lymphoma

    Article • Journal of Clinical Oncology, September 2005, American Society of Clinical Oncology (ASCO)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  231. Another Piece of the MALT Lymphomas Jigsaw

    Article • Journal of Clinical Oncology, August 2005, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  232. Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

    Article • Journal of Clinical Oncology, August 2005, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  233. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas

    Article • Annals of Oncology, July 2005, Elsevier

    Prof. Emanuele Zucca

  234. Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori Therapy

    Article • Journal of Clinical Oncology, March 2005, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  235. Mantle cell lymphoma

    Article • Current Opinion in Hematology, November 2004, Wolters Kluwer Health

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  236. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’1

    Article • British Journal of Haematology, October 2004, Wiley

    Prof. Emanuele Zucca

  237. Follicular Lymphoma International Prognostic Index

    Article • Blood, September 2004, American Society of Hematology

    Prof. Emanuele Zucca

  238. Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma

    Article • Annals of Oncology, August 2004, Elsevier

    Prof. Emanuele Zucca

  239. ChlVPP/ABVVP, a first line ‘hybrid’ combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis

    Article • British Journal of Haematology, April 2004, Wiley

    Prof. Emanuele Zucca

  240. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

    Article • Blood, February 2004, American Society of Hematology

    Prof. Emanuele Zucca

  241. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research

    Article • British Journal of Haematology, January 2004, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  242. Molecular basis of mantle cell lymphoma

    Article • British Journal of Haematology, December 2003, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  243. Pathobiology of Primary Mediastinal B-Cell Lymphoma

    Article • Leukemia & Lymphoma, November 2003, Taylor & Francis

    Prof. Emanuele Zucca

  244. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type

    Article • Blood, October 2003, American Society of Hematology

    Prof. Emanuele Zucca

  245. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma

    Article • British Journal of Haematology, October 2003, Wiley

    Prof. Emanuele Zucca

  246. Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002

    Article • Journal of Clinical Oncology, June 2003, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  247. International Collaborative Group Against Primary CNS Lymphomas

    Article • Journal of Clinical Oncology, April 2003, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  248. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue

    Article • Blood, April 2003, American Society of Hematology

    Prof. Emanuele Zucca

  249. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

    Article • Journal of Clinical Oncology, January 2003, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  250. Efficacy of Vinblastine, Bleomycin, Methotrexate (VBM) Combination Chemotherapy with Involved Field Radiotherapy in Early Stage (I-IIA) Hodgkin Disease Patients

    Article • Leukemia & Lymphoma, January 2003, Taylor & Francis

    Prof. Emanuele Zucca

  251. ACOD, a Modified CHOP Regimen for Elderly Patients with Aggressive Non-Hodgkin's Lymphoma

    Article • Leukemia & Lymphoma, January 2003, Taylor & Francis

    Prof. Emanuele Zucca

  252. Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group

    Article • Journal of Clinical Oncology, January 2003, American Society of Clinical Oncology (ASCO)

    Prof. Emanuele Zucca

  253. Primary Mediastinal B-Cell Lymphoma

    Article • American Journal Of Pathology, January 2003, Elsevier

    Prof. Emanuele Zucca

  254. Mantle Cell Lymphoma: New Treatments Targeted to the Biology

    Article • Clinical Lymphoma, September 2002, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  255. Treatment of extranodal lymphomas

    Article • Best Practice & Research Clinical Haematology, September 2002, Elsevier

    Prof. Emanuele Zucca

  256. The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B-cell and diffuse large B-cell histologies

    Article • British Journal of Haematology, July 2002, Wiley

    Prof. Emanuele Zucca

  257. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial

    Article • Blood, April 2002, American Society of Hematology

    Prof. Emanuele Zucca

  258. Relevance of intraocular involvement in the management of primary central nervous system lymphomas

    Article • Annals of Oncology, April 2002, Elsevier

    Prof. Emanuele Zucca

  259. Genetic alterations underlying the pathogenesis of MALT lymphoma

    Article • The Hematology Journal, January 2002, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  260. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies

    Article • Blood, November 2001, American Society of Hematology

    Prof. Emanuele Zucca, FRANCESC SOLE

  261. Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes

    Article • Blood, August 2001, American Society of Hematology

    Prof. Emanuele Zucca

  262. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

    Article • Annals of Oncology, July 2001, Elsevier

    Prof. Emanuele Zucca

  263. Localized non-Hodgkin's lymphoma of Waldeyer's ring: Clinical features, management, and prognosis of 130 adult patients

    Article • Head & Neck, January 2001, Wiley

    Prof. Emanuele Zucca

  264. Primary intestinal diffuse large B-cell non-Hodgkin's lymphoma: Clinical features, management, and prognosis of 66 patients

    Article • Annals of Oncology, January 2001, Elsevier

    Prof. Emanuele Zucca

  265. Analysis ofFas/CD95 gene somatic mutations in ovarian cancer cell lines

    Article • International Journal of Cancer, May 2000, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  266. BCL10 gene mutations rarely occur in lymphoid malignancies

    Article • Leukemia, April 2000, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  267. Molecular detection of circulating neoplastic cells in patients with clinically localised gastric and non-gastric mucosa-associated lymphoid tissue lymphoma

    Article • Digestive and Liver Disease, April 2000, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  268. Association of gastric and Waldeyer's ring lymphoma: a molecular study

    Article • Hematological Oncology, March 2000, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  269. Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas

    Article • Leukemia, March 2000, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  270. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin

    Article • Human Pathology, February 2000, Elsevier

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  271. Extranodal Marginal Zone B-Cell Lymphoma Genotyping byAlu— Polymerase Chain Reaction

    Article • Leukemia & Lymphoma, January 2000, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  272. Prognostic models for diffuse large b-cell lymphoma

    Article • Hematological Oncology, January 2000, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  273. Extranodal lymphomas

    Article • Annals of Oncology, January 2000, Elsevier

    Prof. Emanuele Zucca

  274. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma

    Article • Annals of Oncology, December 1999, Elsevier

    Prof. Emanuele Zucca

  275. Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study

    Article • Annals of Oncology, November 1999, Elsevier

    Prof. Emanuele Zucca

  276. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites

    Article • Annals of Oncology, September 1999, Elsevier

    Prof. Emanuele Zucca

  277. Microsatellite instability in gastric MALT lymphomas and other associated neoplasms

    Article • Annals of Oncology, July 1999, Elsevier

    Prof. Emanuele Zucca

  278. Molecular Genetics of Extranodal Marginal Zone (MALT-Type) B-Cell Lymphoma

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  279. Immunoglobulin Light Chain Kappa Deletion Rearrangement as a Marker of Clonality in Mantle Cell Lymphoma

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  280. Primary Mediastinal Large B-Cell Lymphoma: The Need for Prospective Controlled Clinical Trials

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  281. Primary Mediastinal Large B-Cell Lymphoma (PMLCL): The Need for Prospective Controlled Clinical Trials

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  282. ChlVPP/ABV-VP16 Hybrid Regimen for Advanced Hodgkin's Disease: a Study in 36 Patients

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Prof. Emanuele Zucca

  283. Clonality Assessment in Blood of Patients with Mantle Cell Lymphoma

    Article • Leukemia & Lymphoma, January 1999, Taylor & Francis

    Prof. Emanuele Zucca

  284. Cardiac involvement in HIV-related non-Hodgkin's lymphoma: a case report and short review of the literature

    Article • Annals of Hematology, August 1998, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  285. Report of the European Task Force on Lymphomas: Workshop on peripheral T-cell lymphomas

    Article • Annals of Oncology, August 1998, Elsevier

    Prof. Emanuele Zucca

  286. Therapeutic use of monoclonal antibodies: A new era?

    Article • Annals of Oncology, July 1998, Elsevier

    Prof. Emanuele Zucca

  287. Distribution of Mobilized Progenitor Cells in the Buffy Coat of the Haemonetics MCS3p Cell Separator: A Study to Optimize the Collection of Progenitors by Leukapheresis

    Article • Journal of Hematotherapy, June 1998, Mary Ann Liebert Inc

    Prof. Emanuele Zucca

  288. Molecular Analysis of the Progression from Helicobacter pylori –Associated Chronic Gastritis to Mucosa-Associated Lymphoid-Tissue Lymphoma of the Stomach

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 1998, New England Journal of Medicine (NEJM/MMS)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  289. Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach

    Article • Leukemia, February 1998, Springer Science + Business Media

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  290. Gastric Mucosa-Associated Lymphoid Tissue Lymphomas: More Than a Fascinating Model

    Article • JNCI Journal of the National Cancer Institute, September 1997, Oxford University Press (OUP)

    Prof. Emanuele Zucca

  291. Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas

    Article • Annals of Oncology, August 1997, Elsevier

    Prof. Emanuele Zucca

  292. Angiotropic (Intravascular) Large Cell Lymphoma: Case Report and Short Discussion of the Literature

    Article • Tumori Journal, July 1997, SAGE Publications

    Prof. Emanuele Zucca

  293. Clinical relevance of bcl-2(MBR)/JH rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma

    Article • British Journal of Cancer, July 1997, Springer Science + Business Media

    Prof. Emanuele Zucca

  294. Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALT‐type gastric lymphoma B cells have undergone an antigen selection process

    Article • British Journal of Haematology, June 1997, Wiley

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  295. Clinical Features, Treatment and Outcome in a Series of 93 Patients with Low-Grade Gastric MALT Lymphoma

    Article • Leukemia & Lymphoma, January 1997, Taylor & Francis

    Prof. Emanuele Zucca

  296. Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas

    Article • Annals of Oncology, December 1996, Oxford University Press (OUP)

    Dr Francesco Bertoni, Prof. Emanuele Zucca

  297. 6 Gut lymphomas

    Article • Baillière s Clinical Haematology, December 1996, Elsevier

    Prof. Emanuele Zucca

  298. 2-Chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III–IV non-Hodgkin's lymphoma

    Article • Annals of Oncology, October 1996, Elsevier

    Prof. Emanuele Zucca

  299. Biology and treatment of MALT lymphoma: The state-of-the-art in 1996

    Article • Annals of Oncology, October 1996, Elsevier

    Prof. Emanuele Zucca

  300. Cell cycle regulation and the function of cancer genes

    Article • Annals of Oncology, December 1995, Elsevier

    Prof. Emanuele Zucca

  301. High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma

    Article • Annals of Oncology, September 1995, Elsevier

    Prof. Emanuele Zucca

  302. Eradication of Helicobacter pylori Infection in Primary Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue

    Article • Annals of Internal Medicine, May 1995, American College of Physicians

    Prof. Emanuele Zucca

  303. Detection of chromosome 11 alterations in blood and bone marrow by interphase cytogenetics in mantle cell lymphoma

    Article • British Journal of Haematology, March 1995, Wiley

    Prof. Emanuele Zucca

  304. Patterns of survival in mantle cell lymphoma

    Article • Annals of Oncology, March 1995, Elsevier

    Prof. Emanuele Zucca

  305. Book review

    Article • Annals of Oncology, November 1994, Elsevier

    Prof. Emanuele Zucca

  306. Book review

    Article • Annals of Oncology, October 1994, Elsevier

    Prof. Emanuele Zucca

  307. European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL)

    Article • Annals of Oncology, July 1994, Elsevier

    Prof. Emanuele Zucca

  308. Treatment and Prognosis of Centrocytic (Mantle Cell) Lymphoma: A Retrospective Analysis of Twenty-six Patients Treated in One Institution

    Article • Leukemia & Lymphoma, January 1994, Taylor & Francis

    Prof. Emanuele Zucca

  309. Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: concordant results of peripheral blood and bone marrow analysis at diagnosis

    Article • British Journal of Cancer, May 1993, Springer Science + Business Media

    Prof. Emanuele Zucca

  310. Book review

    Article • Annals of Oncology, October 1991, Elsevier

    Prof. Emanuele Zucca

  311. Direct sequence analysis of 14q+ and 18q- chromosome junctions at the MBR and MCR revealing clustering within the MBR in follicular lymphoma

    Article • Annals of Oncology, February 1991, Elsevier

    Prof. Emanuele Zucca

  312. Enzymuria in Carboplatin Nephrotoxicity

    Article • Tumori Journal, October 1987, SAGE Publications

    Prof. Emanuele Zucca

  313. Polarographic Assay of Submicrogram Quantities of Cis-Dichlorodiamineplatinum (II) in Biological Samples

    Article • Tumori Journal, October 1983, SAGE Publications

    Prof. Emanuele Zucca

  314. MALT and other marginal zone lymphomas

    Article • Cambridge University Press

    Dr Francesco Bertoni, Prof. Emanuele Zucca